RecruitingNCT06693037

Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

A Cohort Study of Different Choice of Adjuvant Therapy in Non-PCR Patients With HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

Sponsor

Shu Wang

Enrollment

2,092 participants

Start Date

Jan 1, 2019

Study Type

OBSERVATIONAL

Conditions

HER2-positive Breast Cancer

Summary

Chemotherapy combined with trastuzumab and patuzumab is the standard neoadjuvant therapy for HER2 positive breast cancer patients. The survival rate of patients with pathological complete response (PCR) after neoadjuvant therapy was significantly better than that of patients with tumor residue, that is, non-PCR. Therefore, studies have confirmed that adjuvant therapy for patients with non-PCR after neoadjuvant chemotherapy can further improve the prognosis and survival of this population. However, the results of previous studies are based on trastuzumab target therapy in neoadjuvant therapy. Therefore, there are different recommendations for the current guidelines of adjuvant therapy after trastuzumab combined pertuzumab target neoadjuvant therapy. Patients with HER2 positive breast cancer who received trastuzumab and patuzumab based neoadjuvant therapy had invasive residual cancer in postoperative pathology. The effect of postoperative adjuvant therapy with trastuzumab and patuzumab or replacement of T-DM1 on survival.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is analyzing treatment outcomes in patients with HER2-positive early breast cancer who did not achieve a complete pathological response (meaning some cancer cells remained) after receiving targeted drug therapy and chemotherapy before surgery. Researchers want to find out which follow-up treatments work best in this situation. **You may be eligible if...** - You have HER2-positive breast cancer diagnosed at Peking University People's Hospital - Your cancer was stage I–IV but had not spread to other organs - You received at least 4 cycles of chemotherapy combined with trastuzumab and pertuzumab before surgery - After surgery, cancer cells were still found in the breast tissue or lymph nodes - You have agreed to participate in the hospital's breast cancer research program **You may NOT be eligible if...** - Your medical or pathological records are incomplete - Your cancer had spread to other organs, or you have cancer in both breasts - You did not complete surgical removal - You received a non-standard chemotherapy regimen before surgery Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.